TRASTUZUMAB-INDUCED RESPIRATORY DISTRESS: A CASE REPORT
DOI:
https://doi.org/10.22159/ajpcr.2018.v11i10.24343Keywords:
Trastuzumab, Pulmonary toxicity, Breast cancerAbstract
Trastuzumab is a monoclonal antibody effective in treating metastatic breast carcinomas. Cardiotoxicity is the most commonly reported adverse event occurring when used in combination with anthracycline derivatives. Even though pulmonary toxicities are uncommon, immediate withdrawal of the drug is recommended and only reinitiates after the vitals of the patient have become normal. Here, we discuss the case of an 81-year-old female patient who was treated with Injection Trastuzumab for the treatment of breast cancer with metastasis to lungs and received 6 cycles without any major complications. However, 24 h post the last dose; the patient developed a sudden onset of breathlessness and desaturation and was intubated in view of severe metabolic and respiratory acidosis. Blood investigations revealed elevated brain natriuretic peptide, aspartate transaminase, and alkaline phosphatase. Her blood and urine cultures were found to be sterile. She was managed with IV antibiotics, nebulizations, IV fluids, and other supportive medications and had improved considerably. However, on the 11th day, her condition had deteriorated and developed bradycardia. The patient could not be revived and died. Review of the patient's medication did not reveal the presence of any other possible drugs capable of producing pulmonary toxicity. Trastuzumab should be avoided in patients with underlying respiratory or cardiac issues.
Downloads
References
Keefe DL. Trastuzumab-associated cardiotoxicity. Cancer 2002;95:1592.
Chaudhuri T, Karmakar S. Trastuzumab-induced pulmonaryfibrosis: A case report and review of literature. Clin Cancer Investig J 2012;1:242-4.
Holla SN, Nayak V, Bairy LK, Tripathy A, Holla S. HER-2 gene, receptors and drug target: A systematic review. Int J Pharm Pharm Sci 2016;4:4-9.
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
Radzikowska E, Szczepulska E, Chabowski M, Bestry I. Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer. Eur Respir J 2003;21:552-5.
Herceptin (Trastuzumab for Injection). FDA Approved Package Insert. US National Library of Medicine. Available from: http://www.dailymed.nlm.nih.gov. [Last accessed on 2010 Dec 02].
Charpidou AG, Gkiozos I, Tsimpoukis S, Apostolaki D, Dilana KD, Karapanagiotou EM, et al. Therapy-induced toxicity of the lungs: An overview. Anticancer Res 2009;29:631-9.
Lakshmi R, Athira R, Mary JT, Vijayalakshmi S. Breast Cancer Factor Preventable and Non-Preventable. India: Department of Pharmacy Practice; 2012.
Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004;22:1063-70.
Clamon G, Herndon J, Kern J, Govindan R, Garst J, Watson D, et al. Lack of trastuzumab activity in nonsmall cell lung carcinoma with over expression of erb-B2:39810: A phase II trial of cancer and leukemia group B. Cancer 2005;103:1670-5.
Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana- Hulin M, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-74.
Abulkhair L, Melouk WL. Delayed Paclitaxel-trastuzumab-Induced interstitial pneumonitis in breast cancer. Case Rep Oncol 2011;4:186-91.
Hemant K, Raisaday A, Sivadasu PR, Uniyal SW, Kumar SH. Cancer nanotechnology: Nanoparticulate drug delivery for the treatment of cancer. Int J Pharm Pharm Sci 2015;7:40-6.
Zheng H, Reyentovich A, Nierodizik ML, Katz SD. Trastuzumab induced diastolic heart failure. Case Rep Int Med 2015;2:81.
Cook-Burns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001;61 Suppl 2:58-66.
Vahid B, Mehrotra A. Trastuzumab (Herceptin)-associated lung injury. Respirology 2006;11:655-8.
Baselga J, Carbonell X, Castañeda-Soto NJ, Clemens M, Green M, Harvey V, et al. Phase II study of efficacy, safety and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005;23:2162-71.
Published
How to Cite
Issue
Section
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
